<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317472</url>
  </required_header>
  <id_info>
    <org_study_id>MSA-NC-DEX-115</org_study_id>
    <nct_id>NCT01317472</nct_id>
  </id_info>
  <brief_title>The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux</brief_title>
  <official_title>A Double-Blinded, Placebo-Controlled Trial to Investigate Dexlansoprazole for the Treatment of Laryngopharyngeal Reflux</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have demonstrated that patients with throat-related reflux often require twice
      daily proton pump inhibitor therapy to attain significant symptomatic improvement, with once
      daily therapy offering little relief. As dexlansoprazole is a twice-daily release proton pump
      inhibitor requiring only once-daily dosing, it may provide laryngopharyngeal reflux (LPR)
      symptomatic relief comparable to that of twice daily dosing, yet be more readily approved by
      third party payers because of its once daily dosing requirements. It is hypothesized that, in
      patients with pharyngeal-probe proven throat reflux, there will be significantly greater
      improvement in symptoms and pharyngeal probe findings in those patients receiving
      dexlansoprazole than those receiving placebo alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to compare outcomes, based on RSI-based symptomatic improvement and
      pharyngeal probe results, after LPR patients are treated for two months with once-daily (QAM)
      Kapidex versus placebo.Forty patients with pharyngeal pH probe-documented LPR and an elevated
      reflux symptom index (RSI) (≥14) will be enrolled into a double-blinded placebo controlled
      study. Twenty patients will receive Kapidex once daily, while twenty receive placebo.
      Patients will return at two months for evaluation with repeat RSI documentation and repeat
      pharyngeal pH probe testing. Student t-test will be used to determine if the change in RSI
      and pH-probe results differs between the study and placebo group.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principal investigator left institution
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Reflux Symptom Index (RSI)</measure>
    <time_frame>Baseline to 2 months</time_frame>
    <description>The Reflux Symptom Index (RSI) is a 9-item measure with each symptom rated from 0 (no problem) to 5 (severe problem), for a total possible range of 0 (no problem) to 45 (severe problem). An RSI of &gt;13 is considered to be abnormal.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Laryngopharyngeal Reflux</condition>
  <arm_group>
    <arm_group_label>Dexlansoprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexlansoprazole</intervention_name>
    <description>60 mg dexlansoprazole QAM (1 hour AC) for 2 months</description>
    <arm_group_label>Dexlansoprazole</arm_group_label>
    <other_name>Dexilant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 tablet of placebo QAM (1 hour AC) for 2 months</description>
    <arm_group_label>Sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:patients with an abnormal Restech pH probe study and also have an RSI of
        14 or greater will be invited to participate in the study

        Exclusion Criteria:known intolerance or allergy to proton pump inhibitors, hypersecretory
        conditions (Zollinger-Ellison), self-reported anxiety/depression (shown to affect RSI),16
        history of laryngeal irradiation, or have been on twice daily Proton pump inhibitors (PPI)
        therapy for greater than 2 months without symptomatic relief (with an RSI ≥14)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacey L Halum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clarian North Hospital -- IUMG Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 16, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2011</study_first_posted>
  <results_first_submitted>August 29, 2016</results_first_submitted>
  <results_first_submitted_qc>September 6, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 1, 2019</results_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>laryngopharyngeal reflux, acid reflux, throat reflux</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Laryngopharyngeal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexlansoprazole</title>
          <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
dexlansoprazole: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
dexlansoprazole: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated hospitalization</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexlansoprazole</title>
          <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
dexlansoprazole: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
dexlansoprazole: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Reflux Symptom Index (RSI)</title>
        <description>The Reflux Symptom Index (RSI) is a 9-item measure with each symptom rated from 0 (no problem) to 5 (severe problem), for a total possible range of 0 (no problem) to 45 (severe problem). An RSI of &gt;13 is considered to be abnormal.</description>
        <time_frame>Baseline to 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexlansoprazole</title>
            <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
dexlansoprazole: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
dexlansoprazole: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Reflux Symptom Index (RSI)</title>
          <description>The Reflux Symptom Index (RSI) is a 9-item measure with each symptom rated from 0 (no problem) to 5 (severe problem), for a total possible range of 0 (no problem) to 45 (severe problem). An RSI of &gt;13 is considered to be abnormal.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="3.95"/>
                    <measurement group_id="O2" value="13" spread="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexlansoprazole</title>
          <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC).
dexlansoprazole: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Patients who agree to participate in the study will be randomized to receive 60 mg po QAM Kapidex (1 hour AC) or 1 tablet of placebo QAM (1 hour AC).
dexlansoprazole: 60 mg dexlansoprazole QAM (1 hour AC) for 2 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>very poor recruitment. patients were not willing to enter study because they did not want to take a chance on receiving placebo.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Terese Stevens, Dept administrator</name_or_title>
      <organization>Indiana University</organization>
      <phone>317-278-3187</phone>
      <email>tstevens@iupui.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

